TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
MENLO PARK, Calif., April 09, 2017 -- Geron Corporation (Nasdaq:GERN) will host a conference call on April 10, 2017, at 8:00 a.m. Eastern Time to provide an update on the ongoing imetelstat Phase 2/3 trial in myelodysplastic syndromes and the Phase 2 trial in myelofibrosis.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID number is 6116409. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast will also be available through the company’s website at www.geron.com in the Investors section under Events and at http://edge.media-server.com/m/p/w5mtfw9k. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through May 11, 2017.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
